Literature DB >> 16451058

Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.

Giorgio Pochetti1, Enrico Gavuzzo, Cristina Campestre, Mariangela Agamennone, Paolo Tortorella, Valerio Consalvi, Carlo Gallina, Oliver Hiller, Harald Tschesche, Paul A Tucker, Fernando Mazza.   

Abstract

Potent and selective inhibitors of matrix metalloproteinases (MMPs), a family of zinc proteases that can degrade all the components of the extracellular matrix, could be useful for treatment of diseases such as cancer and arthritis. The most potent MMP inhibitors are based on hydroxamate as zinc-binding group (ZBG). alpha-Arylsulfonylamino phosphonates incorporate a particularly favorable combination of phosphonate as ZBG and arylsulfonylamino backbone so that their affinity exceptionally attains the nanomolar strength frequently observed for hydroxamate analogues. The detailed mode of binding of [1-(4'-methoxybiphenyl-4-sulfonylamino)-2-methylpropyl]phosphonate has been clarified by the crystal structures of the complexes that the R- and S-enantiomers respectively form with MMP-8. The reasons for the preferential MMP-8 inhibition by the R-phosphonate are underlined and the differences in the mode of binding of analogous alpha-arylsulfonylamino hydroxamates and carboxylates are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16451058     DOI: 10.1021/jm050787+

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

Review 1.  Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.

Authors:  György Dormán; Sándor Cseh; István Hajdú; László Barna; Dénes Kónya; Krisztina Kupai; László Kovács; Péter Ferdinandy
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 3.  Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.

Authors:  Elisabeth MacColl; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2015-08-28       Impact factor: 4.030

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

5.  An Overview of Stereoselective Synthesis of α-Aminophosphonic Acids and Derivatives.

Authors:  Mario Ordóñez; Haydée Rojas-Cabrera; Carlos Cativiela
Journal:  Tetrahedron       Date:  2009-01-03       Impact factor: 2.457

Review 6.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 7.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

8.  Thioredoxin fusion construct enables high-yield production of soluble, active matrix metalloproteinase-8 (MMP-8) in Escherichia coli.

Authors:  M L McNiff; E P Haynes; N Dixit; F P Gao; J S Laurence
Journal:  Protein Expr Purif       Date:  2016-02-23       Impact factor: 1.650

9.  In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover.

Authors:  Marianna De Colli; Paolo Tortorella; Guya Diletta Marconi; Mariangela Agamennone; Cristina Campestre; Marilena Tauro; Amelia Cataldi; Susi Zara
Journal:  Clin Oral Investig       Date:  2015-12-22       Impact factor: 3.573

10.  Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.

Authors:  Kimberly M Maize; Elbek K Kurbanov; Rodney L Johnson; Elizabeth Ambrose Amin; Barry C Finzel
Journal:  FEBS Lett       Date:  2015-11-11       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.